Recent periods of financial stress and the proliferation of risks across the financial system are fueling the development of ...

Transparency Report revealed that global law enforcement and regulatory agency requests to the exchange in 2024 rose by about 39%. U.S. enforcement agencies made the most requests to the exchange ...

The cuts at the FDA’s device center could add “months, if not years” to the time it takes to bring products to market, an ...

As discussions intensify about how the second Trump administration will reshape the regulatory landscape for U.S.-based life sciences firms, ...

AI agents can never be deployed to handle highly regulated processes. The lack of consistency and data security risks are too ...

In particular, the cuts could hurt the FDA's efforts to scale up its expertise and review capabilities in emerging areas like digital- and AI-based devices.

Researchers have suggested that uniform evidence standards and reporting requirements could help speed patient access to cell and gene therapies and help ensure consistent safety and efficacy ...

U.S. FDA classifies Aurobindo Pharma warehouse in New Jersey as Official Action Indicated, impacting compliance and ...